|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Artificial Intelligence Transformative in Prostate Cancer Patient Care
|
Felix Feng, MD
Felix Feng joins Alicia Morgans to discuss how the application of artificial intelligence (AI) is transformative in prostate cancer care.
|
|
|
|
|
|
|
|
|
|
|
| Beyond Genomics: AI Informing Decision Making in Prostate Cancer |
Ashley Ross, MD, Ph.D.
Ashely Ross discusses the current clinical landscape of how risk is defined in localized prostate cancer highlighting a novel artificial intelligence (AI) derived digital pathology-based biomarker test for prostate cancer, Artera. |
|
|
|
|
|
|
|
|
|
|
| External Validation of a Digital Pathology-Based AI Model Predicting Metastasis and Death in High and Very High Risk Men on NRG/RTOG 9902 Phase III Trial
|
| Ashley E. Ross, MD, Ph.D.
|
| Ashley Ross presents the results of an external validation of a digital pathology-based artificial intelligence (AI) model predicting metastasis and death in high and very high risk men from the NRG/RTOG 9902 phase III trial.
|
|
|
|
|
|
| Prostate Cancer Therapy Personalization via Multi-Modal Deep Learning on Randomized Phase III Clinical Trials
|
| Andre Esteva, Jean Feng, Douwe van der Wal et al. |
| There remains a significant need for accurate and scalable tools to support therapy personalization. This study demonstrates prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies.
|
|
|
|
|
|
| The Hierarchical Relationships Between Deep Learning, Machine Learning, and Artificial Intelligence
|
| Quynh-Thu X. Le, MD
|
| During a session discussing machine learning in radiation oncology clinical trials and clinical practice with Quynh Thu Le presents the latest updates in this field. Dr. Le began her presentation by highlighting the hierarchical relationships between deep learning, machine learning, and artificial intelligence.
|
|
|
|
|
|
| Optimizing Management of Localized Prostate Cancer: Combined Modality Therapy in Localized Disease
|
| Mary-Ellen Taplin, MD
|
| Mary-Ellen Taplin discusses combined modality therapy in localized prostate cancer. Dr. Taplin notes that high-risk localized prostate cancer is associated with an increased risk of morality
|
|
|
|
|
|
| Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology |
| Jonathan Tward, MD, Ph.D., FASTRO
|
Jonathan Tward discusses prostate cancer risk stratification using multimodal deep learning with digital histopathology, within the context of NRG Oncology phase III trials.
|
|
|
|
|
|
| Development and Validation of a Prognostic AI Biomarker Using Multi-Modal Deep Learning with Digital Histopathology in Localized Prostate Cancer on NRG Oncology Phase III Clinical Trials
|
| Osama Mohamad, MD, Ph.D.
|
| Osama Mohamad discusses the development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials. Prognostication in localized prostate cancer is reliant on non-specific tools, an issue that leads to the over-and under-treatment of patients.
|
|
|
|
|
|
